Erbitux is a monoclonal antibody drug used to treat certain types of cancer, including lung cancer. It works by blocking the action of a protein called epidermal growth factor receptor (EGFR), which is found on the surface of some cancer cells. This helps to slow down or stop the growth of the cancer cells. Erbitux is usually used in combination with other chemotherapy drugs to treat advanced non-small cell lung cancer (NSCLC). It is also used to treat head and neck cancer, colorectal cancer, and other types of cancer. Erbitux is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC and other types of cancer. It is available in both intravenous and oral formulations. The drug is marketed by Merck & Co. in the United States and by Bristol-Myers Squibb in Europe. Other companies involved in the Erbitux market include Amgen, AstraZeneca, and Eli Lilly. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
